Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myelomonocytic, Juvenile 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, Large B-Cell, Diffuse 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Sezary Syndrome 1Rhabdoid Tumor 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Myeloproliferative Disorders 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1

Interventions

tazemetostat 1Vorinostat 1Topotecan 1Rifampin 1Psychiatric Rehabilitation 1Itraconazole 1Isotretinoin 1Gelclair 1Dexamethasone 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdoid Tumor × Isotretinoin × Other hematologic neoplasm × Clear all
NCT00217412 2014-06-17

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
CNSLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Medulloblastoma, Neuroblastoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Rhabdoid Tumor, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡